Abstract
Background Evidence recommends that vitamin D might be a crucial supportive agent for the immune system, mainly in cytokine response regulation against COVID-19. Hence, we carried out a systematic review and meta-analysis in order to maximize the use of everything that exists about the role of vitamin D in the COVID-19.
Methods A systematic search was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, and Google Scholar (intitle) as well as preprint database of medRxiv, bioRxiv, Research Square, preprints.org, and search engine of ScienceDirect up to October 10, 2020. Studies focused on the role of vitamin D in confirmed COVID-19 patients were entered into the systematic review.
Results Sixteen studies containing 4922 participants entered into the meta-analysis. The meta-analysis indicated that 48% of COVID-19 patients were suffering from vitamin D deficiency (95% CI, 29%-67%), and in 41% of patients, levels of vitamin D were insufficient (95% CI, 10%-82%). The serum 25-hydroxyvitamin D concentration was 18 ng/mL among all COVID-19 patients (95% CI, 13-24). Co-morbidities frequency in COVID-19 patients were as follows: 7.4% cancer, 27.1% chronic kidney disease, 30.4% cardiovascular diseases, 5.1% dementia, 14.5% depression/anxiety, 32.1% diabetes, 47.4% hypertension, 22.0% obesity and 17.5% respiratory diseases. Reported ethnic groups in studies were 1.0% Afro-Caribbean, 10.3% Asian, and 92.1% Caucasian.
Conclusion This study found that the mean serum 25-hydroxyvitamin D level was low in all COVID-19 patients, and most of them were suffering from vitamin D deficiency/insufficiency. The Caucasian was the dominant ethnic group, and the most frequent co-morbidities in COVID-19 patients were hypertension, cardiovascular diseases, chronic kidney disease, diabetes, obesity, and respiratory diseases, which might be affected by vitamin D deficiency directly or indirectly.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
N/A
